UPLIZNA
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuromyelitis Optica Spectrum Disorder
Conditions
Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
Trial Timeline
Apr 15, 2026 → Oct 31, 2032
NCT ID
NCT05909761About UPLIZNA
UPLIZNA is a pre-clinical stage product being developed by Amgen for Neuromyelitis Optica Spectrum Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05909761. Target conditions include Neuromyelitis Optica Spectrum Disorder, Pregnancy Related.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06590051 | Pre-clinical | Active |
| NCT05909761 | Pre-clinical | Recruiting |
Competing Products
8 competing products in Neuromyelitis Optica Spectrum Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab 120 mg | Chugai Pharmaceutical | Approved | 85 |
| Satralizumab + Placebo + Baseline Treatment | Chugai Pharmaceutical | Phase 3 | 77 |
| Satralizumab + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids | Roche | Phase 3 | 77 |
| Satralizumab | Roche | Phase 3 | 77 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Approved | 84 |
| intravenous methylprednisolone | Brain Biotech | Pre-clinical | 15 |